

### This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
<b>Various</b>				
Inflammation; chronic myelogenous leukemia (CML)	5-Lipoxygenase (ALOX5; 5-LO)	<p>An <i>in vitro</i> study identified 5-LO inhibitors that could help treat inflammation and CML. In a cell-free assay and in leukocytes, a thiazolinone-based compound inhibited the activity of 5-LO, which catalyzes the biosynthesis of proinflammatory leukotrienes. Next steps include optimizing the compound and testing it in preclinical models of inflammation and CML.</p> <p>Cornerstone Therapeutics Inc. markets Zylflo CR zileuton, a 5-LO inhibitor, to treat asthma.</p> <p>Merck &amp; Co. Inc.'s 5-LO inhibitor, MK-0633, is in Phase II for chronic obstructive pulmonary disease (COPD).</p> <p>Via Pharmaceuticals Inc.'s 5-LO inhibitor, VIA-2291, is in Phase II for cardiovascular indications.</p> <p><b>SciBX 4(11); doi:10.1038/scibx.2011.322</b>  <b>Published online March 17, 2011</b></p>	Patent application filed; licensing status undisclosed	<p>Hofmann, B. <i>et al. J. Med. Chem.</i>; published online Feb. 22, 2011; doi:10.1021/jm101165z</p> <p><b>Contact:</b> Bettina Hofmann, Goethe University Frankfurt, Frankfurt, Germany  e-mail: <a href="mailto:hofmann@pharmchem.uni-frankfurt.de">hofmann@pharmchem.uni-frankfurt.de</a></p>